AstraZeneca: Aspen Buys Remaining Rights to Anesthetic Portfolio
14 Septiembre 2017 - 1:56AM
Noticias Dow Jones
By Ian Walker
Pharmaceutical company AstraZeneca PLC (AZN.LN) said Thursday
that Aspen Group's (APZ.AU) unit will buy the remaining rights to
its anesthetic medicines for up to $766 million.
Following the initial deal entered into in June 2016--which saw
Aspen Global Incorporated gain exclusive commercialization rights
to the medicines in markets outside the U.S.--Aspen Global will now
buy the remaining rights to Diprivan, EMLA,
Xylocaine/Xylocard/Xyloproct, Marcaine, Naropin, Carbocaine and
Citanest.
It is paying an initial $555 million for the remaining rights to
the intellectual property and manufacturing knowledge related to
the anesthetic medicines, plus a further $211 million based on
performance.
AstraZeneca said it will continue to manufacture and supply the
medicines to Aspen Global during a transition period of up to five
years.
Write to Ian Walker at ian.walker@wsj.com; @IanWalk40289749
(END) Dow Jones Newswires
September 14, 2017 02:41 ET (06:41 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Aspen (ASX:APZ)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Aspen (ASX:APZ)
Gráfica de Acción Histórica
De May 2023 a May 2024
Real-Time news about Aspen Group (Australian Stock Exchange): 0 recent articles
Más de Aspen Stapled Artículos de Noticias